We advised Finnish Industry Investment Ltd (Tesi) in their joint investment with Lifeline Ventures in TILT Biotherapeutics Ltd, a biotechnology company developing cancer immunotherapies. The financing round was EUR 10 million in total.
TILT Biotherapeutics is a clinical-stage biotechnology company. It develops cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate T cell responses.
Finnish Industry Investment Tesi is a state-owned investment company that wants to raise Finland to the front ranks of transformative economic growth by investing in funds and directly in companies. They invest profitably and responsibly, together with co-investors, to create the world’s new success stories. Tesi’s investments under management total EUR 2.4 billion.
